Related Experiment Video
Updated: May 31, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
Nikkia Zarabian1, Mina Farah, Amanda Stines
1All authors are affiliated with the Department of Dermatology, George Washington University School of Medicine and Health, Sciences, Washington, District of Columbia.
Background:
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an increasingly prescribed class of antidiabetic medications with expanded use in chronic weight management. Emerging literature has raised concerns regarding dermatologic adverse effects of GLP-1RAs, including various forms of alopecia.
Objective:
To evaluate the prevalence of GLP-1RA-associated alopecia, differences among agents, and proposed underlying mechanisms.
Materials And Methods:
A scoping review of GLP-1RAs and alopecia was conducted using PubMed, including articles published up to April 2026.
Results:
Current literature presents conflicting evidence regarding the effects of GLP-1RAs on hair loss. Available data suggest an association between GLP-1RAs and telogen effluvium and androgenic alopecia, with risk potentially increasing with longer duration of use, greater weight loss, and higher doses, particularly with tirzepatide and semaglutide. Proposed mechanisms include weight loss-related changes, alterations in dermal white adipose tissue, and hormonal influences, although their relative contributions remain unclear. Conversely, a smaller body of literature suggests improvement in inflammatory alopecia with GLP-1RA use, particularly among patients with metabolic dysfunction.
Conclusion:
Given the increasing use of GLP-1RAs, dermatology practitioners should be aware of their association with alopecia and consider patient counseling, monitoring, and proactive treatment in patients receiving GLP-1RA therapy.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Biguanides and Glitazones
Accessory Structures of the Skin: Hair Growth and Types
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...

